Ipsen – Consolidated Financial Statements – 2022

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

Ipsen presents its half year 2020 results and reinstates guidance for full year 2020

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Ipsen presents strong full-year 2022 results and guidance for 2023

Ipsen delivers strong sales growth in the first nine months of 2022 and confirms its full-year guidance